Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 16, 2026, 12:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2449–2472 of 21,412 matching trials from the live ClinicalTrials.gov search.
Conditions
Breast Cancer
Interventions
gemcitabine/carboplatin, iniparib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Female only
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
18
States / cities
Birmingham, Alabama • Denver, Colorado • Torrington, Connecticut + 15 more
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
ixabepilone
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
New York, New York
Completed Phase 3 Interventional Results available

PLUTO: Pediatric Lipid-redUction Trial of rOsuvastatin

NCT00355615
Conditions
Familial Hypercholesterolemia
Interventions
Rosuvastatin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
10 Years to 17 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
4
States / cities
Los Angeles, California • Hyde Park, New York • Cincinnati, Ohio + 1 more
Conditions
Phenylketonuria
Interventions
rAvPAL-PEG
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
16 Years to 55 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
14
States / cities
Aurora, Colorado • Gainesville, Florida • Chicago, Illinois + 11 more
Conditions
Autoimmune Diseases of the Nervous System, Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Disease Progression, Brain Atrophy
Interventions
Tcelna, Placebo
Biological
Lead sponsor
Opexa Therapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
33
States / cities
Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 28 more
Conditions
Thymoma and Thymic Carcinoma
Interventions
octreotide acetate, prednisone
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
24
States / cities
Palo Alto, California • Stanford, California • Denver, Colorado + 18 more
Conditions
Lymphoma
Interventions
Duvelisib, Rituximab, R-CHOP, Prednisone
Drug
Lead sponsor
SecuraBio
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Miami, Florida
Conditions
Methamphetamine Intoxication, Methamphetamine Disorders, Methamphetamine Abuse
Interventions
Methamphetamine, Sterile Saline, CS-1103
Drug
Lead sponsor
Clear Scientific, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Glendale, California
Conditions
Solid Tumors
Interventions
Cobimetinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
6 Months to 30 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
5
States / cities
Little Rock, Arkansas • Orlando, Florida • Boston, Massachusetts + 2 more
Conditions
Breast Cancer, Psychosocial Effects of Cancer and Its Treatment
Interventions
psychosocial assessment and care, quality-of-life assessment
Procedure
Lead sponsor
Unity Health Toronto
Other
Eligibility
55 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
3
States / cities
Chicago, Illinois • Terre Haute, Indiana • Fairfield, Iowa
Conditions
Glaucoma
Interventions
AR-12286 0.5% ophthalmic solution, AR-12286 0.25% Ophthalmic solution, Latanoprost ophthalmic solution
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
18
States / cities
Inglewood, California • Petaluma, California • Poway, California + 15 more
Conditions
Kidney Cancer
Interventions
sunitinib malate, conventional surgery
Drug · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Acute Biphenotypic Leukemia, Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Undifferentiated Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, Burkitt Leukemia, Burkitt Lymphoma, Chronic Myeloid Leukemia, BCR-ABL1 Positive, Lymphoblastic Lymphoma, Mast Cell Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome
Interventions
Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Cyclophosphamide, Fludarabine, Total-Body Irradiation
Biological · Procedure · Drug + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Kidney Cancer
Interventions
pegylated interferon alfa
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Conditions
Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
dasatinib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Houston, Texas
Conditions
Breast Cancer
Interventions
Eribulin Mesylate, Ixabepilone
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
50
States / cities
Sedona, Arizona • Hawthorne, California • Los Angeles, California + 39 more
Active, not recruiting Phase 1Phase 2 Interventional

APG-115 in Salivary Gland Cancer Trial

NCT03781986
Conditions
Malignant Salivary Gland Cancer, Salivary Gland Cancer
Interventions
APG-115, Carboplatin
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
3
States / cities
Tampa, Florida • Chicago, Illinois • Ann Arbor, Michigan
Conditions
Meningioma
Interventions
Antineoplaston therapy (Atengenal + Astugenal)
Drug
Lead sponsor
Burzynski Research Institute
Other
Eligibility
18 Years to 99 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
Houston, Texas
Conditions
Gastric Adenocarcinoma, GastroEsophageal Cancer
Interventions
Cabozantinib, Pembrolizumab
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Orange, California
Conditions
Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
Interventions
gemcitabine hydrochloride, tanespimycin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Idiopathic Solar Urticaria
Interventions
Titanium dioxide (Ti02) microfine 12.15% alone (formula RV3131A-MV1209), Ti02 pigmentary 3% alone (formula RV3131A-MV1211), bisoctrizole 10% alone (formula RV3131A-MV1237), Ti02 microfine 12.15% + Ti02 pigmentary 3% (formula RV3131A-MV1213), Ti02 microfine 12.15% + bisoctrizole 10% (formula RV3131A-MV1329), Ti02 pigmentary 3% + bisoctrizole 10% (formula RV3131A-MV1212), Ti02 microfine 12.15% + Ti02 pigmentary 3% + bisoctrizole 10% [V0096 CR (formula RV3131A-MV1166)], V0096 CR vehicle (formula RV3131A-MV1197)
Drug
Lead sponsor
Orfagen
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Detroit, Michigan • New York, New York
Conditions
Allogeneic Stem Cell Transplant Recipient
Interventions
Fludarabine, Intermediate-dose Total Body Irradiation (TBI), Post-transplant Cyclophosphamide (PTCy), Tacrolimus, Mycophenolate mofetil (MMF)
Drug · Radiation
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 65 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Hackensack, New Jersey • Neptune City, New Jersey
Conditions
Postoperative Ileus, Colon Cancer, Pain, Postoperative, Postoperative Nausea and Vomiting
Interventions
Acupuncture, Sham Acupuncture
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
New York, New York
Conditions
Endometrial Cancer
Interventions
Carboplatin, Paclitaxel, bevacizumab
Drug
Lead sponsor
David O'Malley
Other
Eligibility
18 Years and older · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Columbus, Ohio